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The purpose. The aim of presented study was to determine the content of ceruloplasmin in patients with comorbidity with chronic obstructive pulmonary disease (COPD) and chronic pancreatitis.
Materials and Methods. 87 patients were examined: 62 individuals with COPD in combination with chronic pancreatitis – main group, and 25 patients with an isolated course of COPD - group of comparison. Standard values obtained when examining 20 practically healthy persons of similar age and gender – control group. Determination of serum level of ceruloplasmin performed by the method of V. Kamyshnikov. Statistical analysis was performed using licensed programs «Microsoft Excel» and «Statistica 6.0».
Results. The study showed that COPD exacerbation was accompanied by an increase of acute phase reactants, namely – ceruloplasmin, as in patients from the group with isolated COPD, as when it is combined with chronic pancreatitis. In patients with a comorbid pathology was found a significant increase of ceruloplasmin content in blood to 415,7±31,0 mg/l, which is 1.5 times the value of healthy individuals - 276,0±33,0 mg/l (p<0.05). At the same time, ceruloplasmin levels in patients with isolated COPD also tended to increase (311,0±28,0 mg/l) and the control numbers exceed 1.1 times, but these differences were not significant (p>0,05). When comparing the performance between groups of examinees significant differences were revealed (p<0,05) in ceruloplasmin activity.
Conclusions. Thus, as a result of studies, it was found that there was an exacerbation of COPD, in the isolated course of disease, just as when it is combined with chronic pancreatitis. There was an observed increased activity of ceruloplasmin, indicating the development of an inflammatory response. At the same time, indexes of patients with comorbidities of COPD and chronic pancreatitis were significantly higher and had significant differences from those in patients with isolated COPD, suggesting a significant increase in systemic inflammatory reactions in comorbidity, even in the remission of concomitant disease.

